Clinical characteristics and outcome of *Penicillium marneffei* infection among HIV-infected patients in northern Vietnam

Mattias Larsson¹²*, Lien Ha Thi Nguyen³, Heiman FL Wertheim¹², Trinh Tuyet Dao³, Walter Taylor¹², Peter Horby¹², Trung Vu Nguyen³, Minh Ha Thi Nguyen⁷, Thuy Le¹²⁴ and Kinh Van Nguyen³

**Abstract**

**Objective:** This study reports the clinical characteristics and outcome of HIV-associated *Penicillium marneffei* infection in northern Vietnam.

**Methods:** We conducted a retrospective chart review of all patients with laboratory confirmed *Penicillium marneffei* infection admitted to the National Hospital for Tropical Diseases in Hanoi, Vietnam, between July 2006 and September 2009.

**Results:** 127 patients with *P. marneffei* infection were identified. All were HIV-infected; median CD4+ T-cell count was 24 cells/μl (IQR:12-48); 76% were men. Common clinical features were fever (92.9%), skin lesions (82.6%), hepatomegaly (61.4%), lymphadenopathy (40.2%), weight loss (59.1%) and cough (49.6%). Concurrent opportunistic infections were present in 22.0%; half of those had tuberculosis. Initial treatment regimens were: itraconazole or ketoconazole capsule (77.2%), amphotericin B (20.5%), and fluconazole (1.6%). In-hospital mortality was 12.6% and showed no significant difference in patients treated with itraconazole (or ketoconazole) and amphotericin B (p = 0.43). Dyspnea, ascites, and increased LDH level were independent predictors of mortality. No seasonality was observed.

**Conclusion:** The clinical features, treatments and outcomes of HIV-associated *P. marneffei* infection in northern Vietnam are similar to those reported in other endemic regions. Dyspnea was an important predictor of mortality. More patients were treated with itraconazole than amphotericin B and no significant difference in treatment outcome was observed. It would be of clinical value to compare the efficacy of oral itraconazole and amphotericin B in a clinical trial.

**Keywords:** Penicillium Marneffei, Penicillosis, HIV, Opportunistic Infections

**Background**

*Penicillium marneffei* can cause a fatal systemic mycosis in immunosuppressed patients and is one of the leading causes of mortality in people living with Human Immunodeficiency Virus (HIV) in South-East Asia [1-3]. Penicillosis presents primarily as a disseminated disease in HIV-infected patients with CD4+ T-cell count <100 cells/μL, involving the blood stream, skin, liver, spleen, lymph nodes, bone marrow, lung and gastrointestinal tract [2,4]. Typical umbilicated skin lesions are present in 70% of patients, facilitating early empirical antifungal therapy and resulting in better outcomes [4]. Laboratory diagnosis is made by microscopy and culture of skin lesions, blood, lymph node, or other body fluids [3]. The majority of patients respond well to either amphotericin B or itraconazole treatment [2,4-6]; however no randomized controlled trials have been conducted to evaluate treatment choices for penicillosis.

**Study design**

We conducted a retrospective patient chart review of all patients with a compatible clinical syndrome and culture confirmed *P. marneffei* infection admitted to the National Hospital for Tropical Diseases (NHTD) in Hanoi.
between July 2006 and September 2009. Data collected included: demographics, admission date, clinical characteristics, HIV status, CD4+ T-cell count, laboratory investigations, concurrent opportunistic infections (OIs), treatment, and hospital outcome. P. marneffei was cultured from clinical specimens according to standard culture techniques [7]. For seasonality analysis, we assessed the number of penicilliosis admissions during dry versus rainy months in relation to all HIV-related admissions identified from hospital records. For outcome analysis three variables were used: 1. Survival including clinical improvement, defined as regression of symptoms such as fever, skin lesions, lymphadenopathy, hepatomegaly and splenomegaly, or resolution; 2. death at hospital discharge; 3. Lost to follow up due to that the patient were taken home or referred to another health facility and could not be contacted. We performed univariate and multivariate logistic regressions using forward stepwise selection of predictor variables. Statistically significant results (p < 0.05) from the univariate analysis were entered into a multivariate logistic regression model where continuous variables were dichotomized based on the mean values and after exclusion of correlated variables. The analysis was performed using Statistics Package of Social Sciences (SPSS version 19, USA).

Results

P. marneffei infection was diagnosed in 127 patients, 42.5% by both blood and skin lesion culture, 29.1% by blood culture alone, and 28.3% by skin lesion culture alone. The average age was 32 years (range 21–50); the majority was male (75.6%), and 81.9% came from provinces outside of Hanoi in northern Vietnam. The reported route of HIV infection was intravenous drug use (IDU) (37.0%), commercial sex (29.9%), husband to wife (15.7%), combination of IDU and commercial sex (7.9%) and unknown (9.0%). 29.9% had been on antiretroviral therapy (ART) prior to the diagnosis of penicilliosis; the mean duration of ART was 10.8 weeks (SD 18.4).

The clinical and laboratory features are shown in Table 1 and Table 2. The median CD4+ T-cell count on admission was 24 cells/μl (IQR: 12–48). Other OIs were diagnosed (n = 28, 22%) patients; including tuberculosis (n = 14, 11.0%), Pneumocystis jirovecii pneumonia (PCP) (n = 6, 4.7%), varicella-zoster virus (n = 4, 3.1%) as well as toxoplasmosis, cytomegalovirus retinitis and herpes simplex virus type 1 infection all (n = 1, 0.8%). Five patients also had bacteremia with the following pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pyogenes and Salmonella spp. Six patients were previously diagnosed and received treatment for penicilliosis; however, none had started ART. In addition to blood and skin lesion cultures, there were 9 CSF cultures performed of which one was positive for P. marneffei and 11 lymph node aspirate cultures were all negative.

The initial choices of antifungal treatments are listed in Table 3. Outcome at discharge was clinical improvement or resolution in 107 (84.2%) patients and death in 16 (12.6%). Nine patients were discharged early due to request from the family members, or referred to other hospital. Five of them were assessed within a month after discharge and four patients were lost to follow-up. The mean duration of treatment in the hospital was 15.5 days (SD 11). For diseased patients deaths occurred early in the course of treatment after an average of 6.6 days (SD 10), compared to survivors, who were treated in average 16.7 days (SD 10)(p < 0.001). Among 98 patients receiving itraconazole or ketoconazole, 85 (86.7%) had an improvement; 13 (13.3%) died. By comparison, among 26 patients receiving amphotericin B, 24 (92.3%) had an improvement; and two (7.7%) patients died. The mortality differences between the two treatment groups did not reach statistical significance (p = 0.43, χ²test).

Results of the logistic regression are shown in Table 1 for clinical variables and Table 2 for laboratory variables. Univariate analysis showed significantly higher risk of death among patients with dyspnea, defined as a combination of subjective sensation of difficulty breathing and observed tachypnea, ascites, jaundice, splenomegaly (Table 1), increased levels of alanine transaminase (AST), bilirubin, lactate dehydrogenase (LDH), white blood cell count, blood urea, thrombocytopenia and prolonged prothrombin time in Table 2). However, in the multivariate analysis, only dyspnea, ascites and increased LDH levels remained independent predictors of mortality. Of the 11 patients that died 6 had dyspnea, none of them had tuberculosis or Pneumocystis jiroveci. However, two were diagnosed with sepsis, one Escherichia coli and one Streptococcus pyogenes. In total 23 patients had X-ray confirmed lesions of the lungs, 5 of these also had dyspnea (p = 0.015), 4 had pulmonary tuberculosis and 2 had Pneumocystis jiroveci, 4 died, of those 2 were diagnosed with tuberculosis. Of the 5 patients with dyspnea and lung lesions one was diagnosed with Pneumocystis jiroveci and none with tuberculosis.

Assessment of seasonality was performed for the year 2007 and 2008. During these two years P.marneffei accounted for 87 of 793 (11.0%) of all HIV related admissions. The number of penicilliosis admissions was 43 during the hot rainy months (May to October) and 44 during the cooler dry months (November to April). The number of all HIV-related admissions was 463 during the rainy months and 330 during the dry months. The proportion of penicilliosis admissions in relation to all HIV-related admissions comparing dry versus rainy season did not show statistically significant difference (p = 0.07, χ²test).
Discussion
Penicilliosis accounted for 11\% of all HIV-related admissions at NHTD in Hanoi during 2007 and 2008 which is higher than the 4.4\% reported from the major referral hospital for infectious diseases in Ho Chi Minh City, southern Vietnam [4]. However as NHTD is a specialized tertiary hospital, and most (82\%) of the cases were referred, and because other epidemiological data were lacking, it cannot be concluded that there is a difference in disease prevalence between northern and southern Vietnam.

Table 1 Clinical features and association with outcome in 127 patients with penicilliosis

| Characteristics  | All N = 127 (100\%) | Fatal Cases N = 16 (13\%) | Non Fatal Cases N = 111 (87\%) | P value | Odds Ratio | 95% Confidence Interval |
|------------------|---------------------|---------------------------|-------------------------------|---------|------------|------------------------|
| Male sex         | 96 (76\%)           | 12 (75\%)                 | 84 (76\%)                     | NS      |            |                        |
| Age              | Mean 32 (SD 5.5)    | Mean 32 (SD 5.7)          | Mean 32 (SD 5.3)              | NS      |            |                        |

Symptoms/Signs

|                      | N (%)   | N (%)   | N (%)   |
|----------------------|---------|---------|---------|
| Fever                | 118 (93\%) | 16 (100\%) | 102 (92\%) |
| Skin lesions         | 105 (83\%) | 13 (81\%) | 92 (83\%)  |
| Weight loss          | 75 (59\%)  | 8 (50\%)  | 67 (60\%)  |
| Cough                | 63 (50\%)  | 6 (38\%)  | 57 (51\%)  |
| Diarrhoea            | 34 (27\%)  | 6 (38\%)  | 28 (25\%)  |
| Lymphadenopathy      | 51 (40\%)  | 5 (31\%)  | 46 (41\%)  |
| Hepatomegaly         | 78 (61\%)  | 12 (75\%) | 66 (59\%)  |
| Splenomegaly         | 46 (37\%)  | 10 (62\%) | 37 (33\%)  |

|                      | N (%)   | N (%)   | N (%)   |
|----------------------|---------|---------|---------|
| Fever                | 118 (93\%) | 16 (100\%) | 102 (92\%) |
| Skin lesions         | 105 (83\%) | 13 (81\%) | 92 (83\%)  |
| Weight loss          | 75 (59\%)  | 8 (50\%)  | 67 (60\%)  |
| Cough                | 63 (50\%)  | 6 (38\%)  | 57 (51\%)  |
| Diarrhoea            | 34 (27\%)  | 6 (38\%)  | 28 (25\%)  |
| Lymphadenopathy      | 51 (40\%)  | 5 (31\%)  | 46 (41\%)  |
| Hepatomegaly         | 78 (61\%)  | 12 (75\%) | 66 (59\%)  |
| Splenomegaly         | 46 (37\%)  | 10 (62\%) | 37 (33\%)  |

**Aspects**

- **Fever**: 118 (93\%) vs 16 (100\%) vs 102 (92\%)
- **Skin lesions**: 105 (83\%) vs 13 (81\%) vs 92 (83\%)
- **Weight loss**: 75 (59\%) vs 8 (50\%) vs 67 (60\%)
- **Cough**: 63 (50\%) vs 6 (38\%) vs 57 (51\%)
- **Diarrhoea**: 34 (27\%) vs 6 (38\%) vs 28 (25\%)
- **Lymphadenopathy**: 51 (40\%) vs 5 (31\%) vs 46 (41\%)
- **Hepatomegaly**: 78 (61\%) vs 12 (75\%) vs 66 (59\%)
- **Splenomegaly**: 46 (37\%) vs 10 (62\%) vs 37 (33\%)

**ASCITES**

- **29 (23\%)** vs **7 (44\%)** vs **22 (20\%)**
- **P value**: 0.040 0.048* 3.1 4.42* 1.1 - 9.4 1.01-19.32*

**Jaundice**

- **17 (15\%)** vs **5 (31\%)** vs **12 (11\%)**
- **P value**: 0.041 3.8 1.1 - 12.6

**Dyspnoea**

- **11 (9\%)** vs **6 (38\%)** vs **5 (4\%)**
- **P value**: 0.000 .013* 12.7 9.50* 3.3 - 49.2 1.62-55.68*

* Significant in binary multiple regression where LDH was dichotomized based on the mean value 1104 with 22 above and 70 below (OR 3.81 95\% CI: 1.0-14.4), SD, standard deviation.

Table 2 Laboratory test results of 127 patients with penicilliosis

| Laboratory findings | All N = 127 (100\%) | Fatal Cases N = 16 (13\%) | Non Fatal Cases N = 111 (87\%) | P value | Odds Ratio | 95% Confidence Interval |
|---------------------|---------------------|---------------------------|-------------------------------|---------|------------|------------------------|
| Hemoglobin (g/L)    | 92 (26) 126 | 95 (24) 16 | 92 (26) 110 | 0.666 |
| AST (U/L)           | 189 (183) 125 | 285 (238) 16 | 175 (170) 109 | 0.024 |
| ALT (U/L)           | 82 (81) 125 | 78 (71) 16 | 82 (83) 109 | 0.841 |
| Albumin (g/L)       | 33.9 (8.4) 101 | 30.2 (8.3) 16 | 34.6 (8.3) 85 | 0.055 |
| Total bilirubin (μmol/L) | 37.5 (54.4) 85 | 49 (57) 16 | 35 (54) 109 | 0.410 |
| LDH (U/L)           | 1104 (1378) 92 | 2501 (2662) 15 | 832 (714) 77 | 0.000 |

**CD4 + T-cell count (cells/μL)**

- **36.9 (37.6) 114** vs **31 (32) 10** vs **38 (38) 104**

**White blood cell count (cells/μL)**

- **5777 (4063) 105** vs **8667 (654) 9** vs **5506 (369) 96**

**Platelets (cells/μL)**

- **134 (100) 126** vs **91 (81) 16** vs **141 (101) 110**

**Prothrombin time**

- **74.4 (28.1) 54** vs **42 (19) 10** vs **82 (25) 44**

**Creatinine (μmol/L)**

- **95.2 (69.4) 120** vs **103 (41) 16** vs **94 (73) 104**

| **Urea** (mmol/L) | **5.96 (3.32) 123** | **8.2 (4.0) 16** | **5.6 (3.1) 107** | **0.003** |

**Positive blood culture**

- **16 (100\%)** vs **75 (68\%)** vs **111 (87\%)
- **P value**: .003 1.2 1.1 - 1.3

**Positive skin culture**

- **8 (50\%)** vs **82 (74\%)** vs **0.75 0.4 0.1 - 1.0

* Significant in binary multiple regression where LDH was dichotomized based on the mean value 1104 with 22 above and 70 below (OR 3.81 95\% CI: 1.0-14.4), SD, standard deviation.
Vietnam. The clinical features of disseminated penicilliosis are consistent with other studies including profound immunosuppression (median CD4+ T-cell count: 24 cells/μl) and high rate of co-infections with other opportunistic pathogens [2,4,6]. One third of the patients were already on ART for in average 10 days, this indicates that many patients had an ongoing *P. marneffei* infection that was not revealed before initiation of ART, but was probably unmasked by immune reconstitution inflammatory syndrome (IRIS) after initiation of ART, this has earlier been reported in a few case studies [8,9].

In our study the presence of dyspnea, ascites, and high LDH levels on admission independently predicted hospital mortality. Of the six patients that had dyspnea and died no one had tuberculosis or *Pneumocystis jiroveci* pneumonia, one was diagnosed with *P. marneffei* pneumonia at the time of death. This may indicate that pulmonary involvement (i.e. *P. marneffei* pneumonia) drives disease severity or that the disease severity result in pulmonary lesions. This is consistent with a prior study showing that high respiratory rates and dyspnea among penicilliosis patients predicted poor hospital outcome [4]. Of the 11 patients with dyspnea 5 also had lung lesions, of these one was diagnosed with *Pneumocystis jiroveci* and non with tuberculosis. Lung involvement of *P. marneffei* has been shown in Taiwan where it was found to be the most common cause of cavities in the lungs of immunosuppressed HIV infected patients [10]. The majority of patients with dyspnea did not have lung lesions, hence the dyspnea might be due to the severe condition with multi-organ involvement and acute respiratory distress syndrome (ARDS). It should be noted that there could be some under diagnosis of tuberculosis due to the poor sensitivity for sputum microscopy and culture in immunosuppressed individuals as well as for *Pneumocystis jiroveci* as microscopy of sputum, obtained by nebulizer or bronchoscopy, is not routinely performed.

Typical skin lesions were present in 80% of patients in this study. The pathogenesis and prognosis of skin involvement is poorly understood. Although a previous study showed that presence of typical skin lesions facilitates early initiation of empirical antifungal treatment and results in better outcome [4], it is unclear whether skin involvement itself is a prognostic marker. In the absence of skin lesions, the differential diagnoses for an AIDS-associated febrile illness with reticuloendothelial system involvement are broad and include: *Mycobacterium tuberculosis*, *Mycobacterium Avium* Complex, histoplasmosis and cryptococcosis among others [11]. This poses a major challenge in diagnosis and treatment, especially in areas with poor access to blood culture and other diagnostic laboratory. Penicilliosis should be considered in all severely immunosuppressed HIV patients with one or more of the common presentations, skin lesions, lymphadenopathy, hepatomegaly, splenomegaly, ascites, jaundice and dyspnoea, who have been in *P. marneffei* endemic areas, and empirical antifungal treatment in very ill patients may be indicated.

In this study 22% of the patients had a concurrent OI; of whom half had tuberculosis. Hence, multiple OIs, particularly pulmonary tuberculosis, need to be considered. Tuberculosis and penicilliosis co-infection poses a major therapeutic dilemma in resource-poor settings as rifampicin is a potent P450 inducer and markedly reduces itraconazole concentrations [12] Amphotericin B is recommended for patients with concurrent tuberculosis treatment. An alternative tuberculosis drug rifabutin is not available in most penicilliosis endemic areas.

The WHO recommended treatment for severe penicilliosis, amphotericin B, was only given to 20.5% of patients. The majority (77.2%) was treated with either itraconazole or ketoconazole. Although itraconazole is a recommended alternative treatment for mild to moderate disease or when amphotericin B is unavailable [13], in Vietnam both mild and severe cases are commonly treated with oral itraconazole because amphotericin B is often not available or is too expensive. In our study there was no significant difference between itraconazole and amphotericin B in treatment outcome. So far no

### Table 3 Initial antifungal treatment and association with outcomes among 126* patients with penicilliosis

|                | All N = 126 (100%) | Fatal Cases N = 16 (13%) | Non Fatal Cases N = 110 (87%) | Pvalue | Odds Ratio | 95% Confidence Interval |
|----------------|---------------------|--------------------------|-----------------------------|--------|------------|------------------------|
| Itraconazole   | 77 (61%)            | 11 (69%)                 | 66 (60%)                    | 0.222  | 1.8        | 0.6 – 5.5              |
| Ketoconazole   | 4 (3%)              | 1 (6%)                   | 3 (3%)                      | 0.420  | 2.4        | 0.2 – 24.6             |
| Amphotericin B | 26 (21%)            | 2 (13%)                  | 24 (22%)                    | 0.35   | 0.5        | 1.1 – 2.6              |
| Fluconazole    | 2 (2%)              | 1 (6%)                   | 1 (1%)                      | 0.237  | 7.3        | 0.4 – 123.5            |
| Itraconazole or Ketoconazole** | 17 (13%)           | 1 (6%)                   | 16 (15%)                    | 0.330  | 0.4        | 0.05 – 3.2             |

*Treatment data lacking for one patient.
**Itraconazole and ketoconazole were used interchangeably based on availability.*
randomized, prospective treatment trials have been conducted to compare the efficacy of different antifungal treatment regimens for penicilliosis.

Compared to northern Thailand and southern Vietnam where cases peak in the rainy season [4], seasonality was not observed in our cohort. It should be noted that our small sample size and short time frame does not enable any conclusive results about seasonality. However, the cool and dry season in northern Vietnam is often damp with high humidity which might have an impact on the reservoirs of *P. marneffei*.

This study shows that penicilliosis in northern Vietnam presents with similar clinical characteristics as in other endemic areas, and that dyspnea is an important predictor of mortality. It is common practice to treat patients with oral itraconazole rather than amphotericin B, and no significant difference in treatment outcome was observed. It would be of clinical value to compare the efficacy of oral itraconazole and amphotericin B in a clinical trial to develop evidenced based guidelines.

**Abbreviations**

HIV: Human Immunodeficiency Virus; NHTD: National Hospital for Tropical Diseases; IDU: Intravenous drug use.

**Competing interests**

The author declares that they have no competing interests.

**Authors’ contributions**

NTLH - conception and design, acquisition of data, analysis and interpretation of data; has been involved in drafting the manuscript and have given final approval of the version to be published. ML - Analysis and interpretation of data; has been involved in drafting the manuscript and have given final approval of the version to be published. HFLW - conception and design, acquisition of data, interpretation of data, revising it critically for important intellectual content and have given final approval of the version to be published. DTT – Laboratory analysis and have given final approval of the version to be published. WT – conception and design, acquisition of data, revising it critically for important intellectual content and have given final approval of the version to be published. PH – conception and design, acquisition of data, interpretation of data, revising it critically for important intellectual content and have given final approval of the version to be published. NVK – conception and design, acquisition of data and have given final approval of the version to be published. All authors read and approved the final manuscript.

**Acknowledgements**

We thank the administration and staff at the National Hospital for Tropical Diseases for giving us access to the hospital admission records, microbiology records, and the hospital charts. We thank the staff at the Clinical Trial Unit and the Data Management Department at the Oxford University Clinical Research Unit for assistance in obtaining the hospital charts and data management. This work was supported by Wellcome Trust Major Overseas Programme. None of the funding sources had any role in the design or execution of the study.

**Author details**

1Oxford University Clinical Research Unit, Welcome Trust Major Overseas Program, Hanoi, Vietnam. 2Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. 3National Hospital for Tropical Diseases, Hanoi, Vietnam. 4Hawaii Center for AIDS, University of Hawaii at Manoa, John A. Burns School of Medicine, Honolulu, HI, USA.

Received: 14 February 2012 Accepted: 14 July 2012 Published: 16 August 2012

**References**

1. Cuong DD, Thorson A, Sonnerborg A, Hoa NP, Chu CT, Phuc HD, et al: Survival and Causes of Death among Vietnamese HIV-infected Patients Starting Antiretroviral Therapy Enrolled in a Cluster Randomized, Controlled Trial. *Scand J Infect Dis*. 2012, 44(3):201–208. Epub 2011 Nov 28.
2. Supparatpinyo K, Kharmawan C, Baocong V, Nelson KE, Siriathana T: Disseminated *Penicillium marneffei* infection in southeast Asia. *Lancet* 1994, 344:110–113.
3. Vanittanakom N, Cooper CR Jr, Fisher MC, Siriathana T: *Penicillium marneffei* infection and recent advances in the epidemiology and molecular biology aspects. *Clin Microbiol Rev* 2006, 19:95–110.
4. Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, et al: Epidemiology, seasonality, and predictors of outcome of AIDS-associated *Penicillium marneffei* infection in Ho Chi Minh City, Viet Nam. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 2011, 52:945–952.
5. Wu TC, Chan JW, Ng CK, Tsang DN, Lee MP, Li PC: Clinical presentations and outcomes of *Penicillium marneffei* infections: a series from 1994 to 2004. *Hong Kong Med J* 2008, 14:103–109.
6. Ranjana KH, Priyokumar K, Singh TJ, Gupta CC, Sharmila L, Singh PN, et al: Disseminated *Penicillium marneffei* infection among HIV-infected patients in Manipur state, India. *J Infect* 2002, 45:268–271.
7. Viviani MATA: *Penicillium marneffei*. In *Microbiology and microbial infections*. Edited by Ajello LH. Topley and Wilson’s; 1998:689–419.
8. Ho A, Shankland GS, Seaton RA: *Penicillium marneffei* infection presenting as an immune reconstitution inflammatory syndrome in an HIV patient. *Int J STD AIDS* 2010, 21:780–782.
9. Saikia L, Nath R, Hazarika D, Mahanta J: Atypical cutaneous lesions of *Penicillium marneffei* infection as a manifestation of the immune reconstitution inflammatory syndrome after highly active antiretroviral therapy. *Indian J Dermatol Venereol Leprol* 2010, 76:45–48.
10. Lin CY, Sun HY, Chen MY, Hsieh SM, Sheng WH, Lo YC, et al: *Atypical cutaneous lesions of Penicillium marneffei infection as a manifestation of the immune reconstitution inflammatory syndrome after highly active antiretroviral therapy*. *Int J Dermatol* 2009, 48:669–680.
11. Cooper CR Jr, McGinnis MR: Pathology of *Penicillium marneffei*. An emerging acquired immunodeficiency syndrome-related pathogen. *Arch Pathol Lab Med* 1997, 121:799–804.
12. Ohno Y, Hirasaka A, Ueno M, Suzuki H: General framework for the prediction of oral drug interactions caused by *CYP3A4* induction from in vivo information. *Clin Pharmacokinet* 2008, 47:669–680.
13. Minister of Health Vietnam: *Guidelines for hiv/aids diagnosis and treatment*. Hanoi: Ministry of Health; 2009.